EUVIMEDEUVIMED entdecken
Crossref

Development of a Novel Mucosal Vaccine Vector Derived From Human Parainfluenza Virus Type 2 and Its Efficacy as a SARS‐CoV‐2 Vaccine by Intratracheal Administration Using Transgenic Mice Expressing Human Angiotensin‐Converting Enzyme 2

Akira Kawano, Masamitsu N Asaka, Mitsuo Kawano iD, Hidehisa Sekijima, Kae Sakai-Sugino, Hiroshi Komada, Natsuko Yamakawa, Shigeo Horibata, Kazuhiro Matsuo, Myles O'Brien, Tetsuya Nosaka, Yasuhiro Yasutomi iD

Genes to Cells · 2025

DOI: 10.1111/gtc.70058 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Genes to Cells, 2025. Verfasst von Akira Kawano und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Molecular Genetics, Mie University Graduate School of Medicine, Tsu, Mie, Japan. Hauptthemen laut MEDLINE: Angiotensin-Converting Enzyme 2, SARS-CoV-2, COVID-19, COVID-19 Vaccines. Die Arbeit nennt 56 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We created a novel replication‐incompetent vector derived from the human parainfluenza virus type 2 (hPIV2). The vector lacks the hemagglutinin‐neuraminidase ( HN ) gene (hPIV2/∆HN) that is essential for virus attachment and release. We also generated the stable packaging cell line expressing hPIV2 HN protein derived from Vero cells (Vero‐HN). As SARS‐CoV‐2 vaccines, we created hPIV2/∆HN‐based SARS‐CoV‐2 vaccines expressing the receptor binding domain of the spike protein (S‐RBD) of SARS‐CoV‐2, and S‐RBD with trimer formation domain (S‐RBD‐FD) with or without antigen 85B (Ag85B) having strong Th1‐type cytokine inducing activity. Intratracheal administration of S‐RBD‐FD/hPIV2/∆HN and S‐RBD‐FD/Ag85B/hPIV2/∆HN induced the S‐RBD‐specific neutralizing antibodies in sera of transgenic mice expressing human angiotensin‐converting enzyme 2 (hACE2/TG), and also the sera neutralized the pseudo‐typed lentivirus expressing the SARS‐CoV‐2 S protein. In particular, in an S‐RBD‐FD/Ag85B/hPIV2/∆HN‐administered group, high levels of neutralizing antibodies were induced also in the bronchoalveolar lavage fluid (BALF) in the hACE2/TG mice. Further, hACE2/TG mice vaccinated with S‐RBD‐FD/hPIV2/∆HN or S‐RBD‐FD/Ag85B/hPIV2/∆HN did not exhibit weight loss and showed a high survival rate after authentic SARS‐CoV‐2 challenge. These results suggested that S‐RBD‐FD/Ag85B/hPIV2/∆HN is a vaccine candidate against SARS‐CoV‐2. Finally, hPIV2/∆HN or Ag85B/hPIV2/∆HN vector will be potentially applicable to vaccine development and/or human gene therapy for respiratory tract diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Angiotensin-Converting Enzyme 2SARS-CoV-2COVID-19COVID-19 VaccinesParainfluenza Virus 2, HumanAnimalsHumansMiceMice, TransgenicSpike Glycoprotein, CoronavirusVero CellsChlorocebus aethiopsGenetic VectorsAntibodies, NeutralizingAntibodies, Viral

Stichwörter der Autor:innen

SARS‐CoV‐2human parainfluenza virus type 2 vectormucosal vaccine

Substanzen

Angiotensin-Converting Enzyme 2Spike Glycoprotein, CoronavirusACE2 protein, humanCOVID-19 VaccinesAntibodies, NeutralizingAntibodies, Viralspike protein, SARS-CoV-2

Autor:innen und Institutionen

  • Department of Microbiology and Molecular Genetics, Mie University Graduate School of Medicine, Tsu, Mie, Japan.
  • Laboratory of Immunoregulation and Vaccine Research, Tsukuba Primate Research Center, National Institute of Biomedical Innovation, Health and Nutrition, Tsukuba, Ibaraki, Japan.
  • Leprosy Research Center, National Institute of Infectious Diseases, Japan Institute for Health Security, Tokyo, Japan.
  • Department of Forensic Medicine and Sciences, Mie University Graduate School of Medicine, Tsu, Mie, Japan.
  • Department of Food and Nutrition, Tsu City College, Tsu, Mie, Japan.
  • Research and Development Department, Japan BCG Laboratory, Tokyo, Japan.

ORCID-Profile: Mitsuo Kawano, Yasuhiro Yasutomi

Förderung

  • Japan Society for the Promotion of Science

Zitieren

APA

Kawano, A., Asaka, M. N., Kawano, M., Sekijima, H., Sakai-Sugino, K., Komada, H., Yamakawa, N., Horibata, S., Matsuo, K., O'Brien, M., Nosaka, T., & Yasutomi, Y. (2025). Development of a Novel Mucosal Vaccine Vector Derived From Human Parainfluenza Virus Type 2 and Its Efficacy as a SARS‐CoV‐2 Vaccine by Intratracheal Administration Using Transgenic Mice Expressing Human Angiotensin‐Converting Enzyme 2. Genes to Cells. https://doi.org/10.1111/gtc.70058

Vancouver

Kawano A, Asaka MN, Kawano M, Sekijima H, Sakai-Sugino K, Komada H, et al. Development of a Novel Mucosal Vaccine Vector Derived From Human Parainfluenza Virus Type 2 and Its Efficacy as a SARS‐CoV‐2 Vaccine by Intratracheal Administration Using Transgenic Mice Expressing Human Angiotensin‐Converting Enzyme 2. Genes to Cells. 2025. doi:10.1111/gtc.70058

BibTeX
@article{Kawano2025,
  author = {Kawano, Akira and Asaka, Masamitsu N and Kawano, Mitsuo and Sekijima, Hidehisa and Sakai-Sugino, Kae and Komada, Hiroshi and Yamakawa, Natsuko and Horibata, Shigeo and Matsuo, Kazuhiro and O'Brien, Myles and Nosaka, Tetsuya and Yasutomi, Yasuhiro},
  title = {Development of a Novel Mucosal Vaccine Vector Derived From Human Parainfluenza Virus Type 2 and Its Efficacy as a SARS‐CoV‐2 Vaccine by Intratracheal Administration Using Transgenic Mice Expressing Human Angiotensin‐Converting Enzyme 2},
  journal = {Genes to Cells},
  year = {2025},
  doi = {10.1111/gtc.70058}
}
Kostenlos starten →